GSK: Oncology data highlighted survival, response and organ-preserving treatment gains

GSK presented ESMO 2026 data showing activity in ris-rez for SCLC and osteosarcoma, mo-rez in platinum-resistant ovarian cancer, and high response rates for dostarlimab and zidesamtinib. The company plans five phase III studies for mo-rez in ovarian and endometrial cancers.

GSK presented data on its oncology pipeline at an investor update, including Phase III study results for ris-rez in osteosarcoma, mo-rez in ovarian cancer, and dostarlimab in rectal cancer. The company also discussed JIDEYTRO for ROS1-positive lung cancer. GSK plans to initiate a first-line study for small-cell lung cancer before year-end. Key data points include median PFS of 5.5 months for ris-rez and a 68% clinical complete response rate for dostarlimab.

GSK and Hansoh Pharma reported that the Phase III ARTEMIS-011 trial of Ris-Rez met its primary endpoint, reducing progression or death risk by 67% in relapsed osteosarcoma patients in China. Median PFS was 5.5 months with Ris-Rez versus 1.4 months with chemotherapy. Results were presented at the ESMO congress and will support a regulatory submission by Hansoh in China.

GSK (LON:GSK) plans to nearly double its clinical-stage oncology portfolio to about 30 assets in 2027, according to a Wall Street Journal report. The company has five approved cancer drugs and aims to expand its pipeline through deals, including a $10.6B acquisition of Nuvalent and a $750M licensing agreement with Chimagen Biosciences. Analysts expect GSK's oncology business to contribute significantly to sales by the end of the decade.

Novartis halted its Alzheimer's drug lifonebart after a biomarker review. Windward Bio filed for a Nasdaq IPO to fund antibody trials. GSK's hepatitis B drug Hibsago won FDA approval. Idorsia plans autism trials for daridorexant. Servier paid Insilico a milestone under their oncology collaboration.

GSK plans to nearly double its cancer drug trials to 19-20 by 2027, according to WSJ. The company's oncology push is part of CEO Luke Miels' strategy to address patent expirations for HIV drugs. GSK's oncology segment generated £1.08 billion in H1 2026.